Current Report Filing (8-k)
November 09 2017 - 05:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO
SECTION 13 OR 15(D)
OF THE SECURITIES
EXCHANGE ACT OF 1934
November
9, 2017 (November 9, 2017)
Date of Report
(Date of earliest event reported)
ELITE
PHARMACEUTICALS, INC.
(Exact name
of registrant as specified in its charter)
Nevada
|
001-15697
|
22-3542636
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
165 Ludlow
Avenue, Northvale, New Jersey 07647
(Address of
principal executive offices)
(201) 750-2646
(Registrant’s
telephone number, including area code)
|
(Former
name or former address, if changed since last report.)
|
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the
registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 2.02.
|
Results of Operations
and Financial Condition.
|
On November 9, 2017, Elite Pharmaceuticals,
Inc. (“Elite” or the “Company”) filed its quarterly report on Form 10-Q for the quarter ended September 30,
2017 and, thereafter, issued a press release announcing its financial results for that quarter. A copy of the press release is
furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
As noted in the press release, the
Company will host a conference call at 11:30 AM Eastern Standard Time (EST) on Friday, November 10, 2017, to provide a general
business update. Elite will respond to various stockholder questions submitted prior to the call.
Conference Call Information
Date:
|
Friday, November 10, 2017
|
Time:
|
11:30 AM EST
|
Dial-in numbers:
|
1-800-346-7359 (domestic)
|
|
1-973-528-0008 (international)
|
Conference number:
|
98840
|
Questions:
|
dianne@elitepharma.com
by 9:00 AM on Friday, November 10, 2017
|
Audio Replay:
|
http://ir.elitepharma.com/events_presentations
|
|
Item 7.01.
|
Regulation FD Disclosure.
|
The information disclosed in Item
2.02 above is incorporated into this Item 7.01. The information included in this Current Report on Form 8-K (including the exhibit
hereto) is being furnished under Item 2.02, “Results of Operations and Financial Condition,” Item 7.01, “Regulation
FD Disclosure” and Item 9.01 “Financial Statements and Exhibits” of Form 8-K. As such, the information (including
the exhibit) herein shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be incorporated
by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation
language in such filing, except as shall be expressly set forth by specific reference in such a filing. This Current Report (including
the exhibit hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to
satisfy the requirements of Regulation FD.
|
Item 9.01.
|
Financial Statements and
Exhibits.
|
(d) Exhibits.
SIGNATURE
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated: November 9, 2017
|
ELITE PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/ Nasrat Hakim
|
|
|
Nasrat Hakim, President and CEO
|
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Feb 2024 to Mar 2024
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Mar 2023 to Mar 2024